EuropaBio statement regarding the re-location of the EMA to Amsterdam
Our take on this evening's voting result in the European Council
EuropaBio and its members welcome the decision of the European Council to provide clarity on the relocation of the European Medicines Agency (EMA) to Amsterdam, ending a prolonged period of uncertainty and speculation around the future location for patients, the EMA agency staff and industry.
“Now that we have more clarity, it is vital that the relocation of the EMA will be carried out in such a way as to minimise as much as possible any disruptions that could negatively affect access to medicines for patients”, said John Brennan, EuropaBio Secretary General.
In a best-case scenario, the relocation process would not impact negatively on regulatory capacity, processes or timeframes for the approval of new and the maintenance of existing medicines. The regulatory system is in place to support patient safety and access to medicines that save and enhance lives.
EuropaBio, representing the innovative healthcare biotech industry, remains fully committed to collaborating with the EMA, the EU institutions, Dutch authorities and the other members of the EU medicines regulatory network to support in any way necessary during the relocation process.